ACC 25 - STRIDE shows subcutaneous semaglutide improved walking ability and related quality of life in patients with both type 2 diabetes and peripheral arterial disease (PAD) with intermittent claudication symptoms.

Late-Breaker host, Dr Harriette Van Spall (McMaster University, Hamilton, CA) is joined by Dr Marc Bonaca (University of Colorado School of Medicine, Aurora, CO, US) to discuss the findings from STRIDE, a randomized-double blind placebo-controlled trial investigating the effect of semaglutide on walking ability in people with PAD and type 2 diabetes. The primary outcome was the change in maximum walking distance on constant load treadmill test from baseline to 52 weeks. Secondary outcomes included pain-free walking distance changes, quality of life measures, metabolic parameters, vascular measurements and follow-up measures at week 57.

Findings showed significantly improved maximum walking distance and pain-free walking distance, meeting prespecified criteria for a clinically meaningful change. The study also showed significant improvement in all supportive secondary outcomes, including qualify of life measures.

Recorded Onsite at ACC 25, Chicago.

Editors: Yazmin Sadik, Jordan Rance

Videographers: Dan Brent, David Ben-Harosh

Support: This is an independent interview produced by Radcliffe Cardiology.